18%的美国大雇主服用减重药品,费用高昂导致覆盖面有限。 18% of large US employers cover weight loss drugs, with high costs contributing to limited coverage.

最近一项健康事务调查显示,美国大雇主中只有18%的人服用Wegovy和Zepbound等体重丧失药物,主要原因是月成本超过1 000美元。 A recent Health Affairs survey reveals that only 18% of large U.S. employers cover weight loss drugs like Wegovy and Zepbound, mainly due to their high monthly costs exceeding $1,000. 国会预算办公室分析估计,扩大这些药品的医疗保险覆盖面到2034年可能耗资350亿美元,肥胖率上升导致需求增加。 A Congressional Budget Office analysis estimates expanding Medicare coverage for these drugs could cost $35 billion by 2034, with rising obesity rates creating more demand. 雇主在将这些昂贵的治疗方法纳入保健计划方面面临着挑战,尽管今后有可能扩大覆盖面。 Employers face challenges in integrating these costly treatments into health plans, despite potential future coverage expansions.